Tonis Org
University of California, Los Angeles
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Tonis Org.
Cell | 2012
Ben Van Handel; Amelie Montel-Hagen; Rajkumar Sasidharan; Haruko Nakano; Roberto Ferrari; Cornelis J. Boogerd; Johann Schredelseker; Yanling Wang; Sean Hunter; Tonis Org; Jian Zhou; Xinmin Li; Matteo Pellegrini; Jau-Nian Chen; Stuart H. Orkin; Siavash K. Kurdistani; Sylvia M. Evans; Atsushi Nakano; Hanna Mikkola
Endothelium in embryonic hematopoietic tissues generates hematopoietic stem/progenitor cells; however, it is unknown how its unique potential is specified. We show that transcription factor Scl/Tal1 is essential for both establishing the hematopoietic transcriptional program in hemogenic endothelium and preventing its misspecification to a cardiomyogenic fate. Scl(-/-) embryos activated a cardiac transcriptional program in yolk sac endothelium, leading to the emergence of CD31+Pdgfrα+ cardiogenic precursors that generated spontaneously beating cardiomyocytes. Ectopic cardiogenesis was also observed in Scl(-/-) hearts, where the disorganized endocardium precociously differentiated into cardiomyocytes. Induction of mosaic deletion of Scl in Scl(fl/fl)Rosa26Cre-ER(T2) embryos revealed a cell-intrinsic, temporal requirement for Scl to prevent cardiomyogenesis from endothelium. Scl(-/-) endothelium also upregulated the expression of Wnt antagonists, which promoted rapid cardiomyocyte differentiation of ectopic cardiogenic cells. These results reveal unexpected plasticity in embryonic endothelium such that loss of a single master regulator can induce ectopic cardiomyogenesis from endothelial cells.
Cell Reports | 2014
Bibhu P. Mishra; Kristin M. Zaffuto; Erika L. Artinger; Tonis Org; Hanna Mikkola; Chao Cheng; Malek Djabali; Patricia Ernst
SUMMARY Despite correlations between histone methyltransferase (HMT) activity and gene regulation, direct evidence that HMT activity is responsible for gene activation is sparse. We address the role of the HMT activity for MLL1, a histone H3 lysine 4 (H3K4) methyltransferase critical for maintaining hematopoietic stem cells (HSCs). Here, we show that the SET domain, and thus HMT activity of MLL1, is dispensable for maintaining HSCs and supporting leukemogenesis driven by the MLL-AF9 fusion oncoprotein. Upon Mll1 deletion, histone H4 lysine 16 (H4K16) acetylation is selectively depleted at MLL1 target genes in conjunction with reduced transcription. Surprisingly, inhibition of SIRT1 is sufficient to prevent the loss of H4K16 acetylation and the reduction in MLL1 target gene expression. Thus, recruited MOF activity, and not the intrinsic HMT activity of MLL1, is central for the maintenance of HSC target genes. In addition, this work reveals a role for SIRT1 in opposing MLL1 function.
The EMBO Journal | 2015
Tonis Org; Dan Duan; Roberto Ferrari; Amelie Montel-Hagen; Ben Van Handel; Marc A. Kerenyi; Rajkumar Sasidharan; Liudmilla Rubbi; Yuko Fujiwara; Matteo Pellegrini; Stuart H. Orkin; Siavash K. Kurdistani; Hanna Mikkola
Scl/Tal1 confers hemogenic competence and prevents ectopic cardiomyogenesis in embryonic endothelium by unknown mechanisms. We discovered that Scl binds to hematopoietic and cardiac enhancers that become epigenetically primed in multipotent cardiovascular mesoderm, to regulate the divergence of hematopoietic and cardiac lineages. Scl does not act as a pioneer factor but rather exploits a pre‐established epigenetic landscape. As the blood lineage emerges, Scl binding and active epigenetic modifications are sustained in hematopoietic enhancers, whereas cardiac enhancers are decommissioned by removal of active epigenetic marks. Our data suggest that, rather than recruiting corepressors to enhancers, Scl prevents ectopic cardiogenesis by occupying enhancers that cardiac factors, such as Gata4 and Hand1, use for gene activation. Although hematopoietic Gata factors bind with Scl to both activated and repressed genes, they are dispensable for cardiac repression, but necessary for activating genes that enable hematopoietic stem/progenitor cell development. These results suggest that a unique subset of enhancers in lineage‐specific genes that are accessible for regulators of opposing fates during the time of the fate decision provide a platform where the divergence of mutually exclusive fates is orchestrated.
Cell | 2014
Lauren M. Goddard; Thomas Murphy; Tonis Org; Josephine Enciso; Minako K. Hashimoto-Partyka; Carmen M. Warren; Courtney K. Domigan; Austin I. McDonald; Huanhuan He; Lauren A. Sanchez; Nancy C. Allen; Fabrizio Orsenigo; Lily C. Chao; Elisabetta Dejana; Peter Tontonoz; Hanna Mikkola; M. Luisa Iruela-Arispe
Vascular permeability is frequently associated with inflammation and is triggered by a cohort of secreted permeability factors such as vascular endothelial growth factor (VEGF). Here, we show that the physiological vascular permeability that precedes implantation is directly controlled by progesterone receptor (PR) and is independent of VEGF. Global or endothelial-specific deletion of PR blocks physiological vascular permeability in the uterus, whereas misexpression of PR in the endothelium of other organs results in ectopic vascular leakage. Integration of an endothelial genome-wide transcriptional profile with chromatin immunoprecipitation sequencing revealed that PR induces an NR4A1 (Nur77/TR3)-dependent transcriptional program that broadly regulates vascular permeability in response to progesterone. Silencing of NR4A1 blocks PR-mediated permeability responses, indicating a direct link between PR and NR4A1. This program triggers concurrent suppression of several junctional proteins and leads to an effective, timely, and venous-specific regulation of vascular barrier function that is critical for embryo implantation.
Vascular Pharmacology | 2013
Lauren M. Goddard; Amy N. Ton; Tonis Org; Hanna Mikkola; M. Luisa Iruela-Arispe
Steroid hormones are well-recognized suppressors of the inflammatory response, however, their cell- and tissue-specific effects in the regulation of inflammation are far less understood, particularly for the sex-related steroids. To determine the contribution of progesterone in the endothelium, we have characterized and validated an in vitro culture system in which human umbilical vein endothelial cells constitutively express human progesterone receptor (PR). Using next generation RNA-sequencing, we identified a selective group of cytokines that are suppressed by progesterone both under physiological conditions and during pathological activation by lipopolysaccharide. In particular, IL-6, IL-8, CXCL2/3, and CXCL1 were found to be direct targets of PR, as determined by ChIP-sequencing. Regulation of these cytokines by progesterone was also confirmed by bead-based multiplex cytokine assays and quantitative PCR. These findings provide a novel role for PR in the direct regulation of cytokine levels secreted by the endothelium. They also suggest that progesterone-PR signaling in the endothelium directly impacts leukocyte trafficking in PR-expressing tissues.
Nature Communications | 2016
Wenyuan Wang; Tonis Org; Amelie Montel-Hagen; Peter D. Pioli; Dan Duan; Edo Israely; Daniel Malkin; Trent Su; Johanna Flach; Siavash K. Kurdistani; Robert H. Schiestl; Hanna Mikkola
DNA double strand break (DSB) repair is critical for generation of B-cell receptors, which are pre-requisite for B-cell progenitor survival. However, the transcription factors that promote DSB repair in B cells are not known. Here we show that MEF2C enhances the expression of DNA repair and recombination factors in B-cell progenitors, promoting DSB repair, V(D)J recombination and cell survival. Although Mef2c-deficient mice maintain relatively intact peripheral B-lymphoid cellularity during homeostasis, they exhibit poor B-lymphoid recovery after sub-lethal irradiation and 5-fluorouracil injection. MEF2C binds active regulatory regions with high-chromatin accessibility in DNA repair and V(D)J genes in both mouse B-cell progenitors and human B lymphoblasts. Loss of Mef2c in pre-B cells reduces chromatin accessibility in multiple regulatory regions of the MEF2C-activated genes. MEF2C therefore protects B lymphopoiesis during stress by ensuring proper expression of genes that encode DNA repair and B-cell factors.
Nature Communications | 2018
Gabriel B. Ferguson; Ben Van Handel; Maxwell Bay; Petko Fiziev; Tonis Org; Siyoung Lee; Ruzanna Shkhyan; Nicholas W. Banks; Mila Scheinberg; Ling Wu; Biagio Saitta; Joseph Elphingstone; A. Noelle Larson; Scott M. Riester; April D. Pyle; Nicholas M. Bernthal; Hanna Mikkola; Jason Ernst; Andre J. van Wijnen; Michael A. Bonaguidi; Denis Evseenko
Tissue-specific gene expression defines cellular identity and function, but knowledge of early human development is limited, hampering application of cell-based therapies. Here we profiled 5 distinct cell types at a single fetal stage, as well as chondrocytes at 4 stages in vivo and 2 stages during in vitro differentiation. Network analysis delineated five tissue-specific gene modules; these modules and chromatin state analysis defined broad similarities in gene expression during cartilage specification and maturation in vitro and in vivo, including early expression and progressive silencing of muscle- and bone-specific genes. Finally, ontogenetic analysis of freshly isolated and pluripotent stem cell-derived articular chondrocytes identified that integrin alpha 4 defines 2 subsets of functionally and molecularly distinct chondrocytes characterized by their gene expression, osteochondral potential in vitro and proliferative signature in vivo. These analyses provide new insight into human musculoskeletal development and provide an essential comparative resource for disease modeling and regenerative medicine.Human development provides a roadmap for advancing pluripotent stem cell-based regenerative therapies. Here the authors mapped human skeletogenesis using RNA sequencing on 5 cell types from a single foetal stage as well as chondrocytes at 4 stages in vivo and 2 stages during in vitro differentiation.
Experimental Hematology | 2018
Fides D. Lay; Hamilton Oh; Dan Duan; Tonis Org; Edo Israely; Hanna Mikkola
Experimental Hematology | 2014
Bibhu P. Mishra; Weiwei Yang; Kristin M. Zaffuto; Erika L. Artinger; Bin E. Li; Chao Cheng; Tonis Org; Hanna Mikkola; Malek Djabali; Patricia Ernst
Experimental Hematology | 2013
Dan Duan; Tonis Org; Roberto Ferrari; Amelie Montel-Hagen; Ben Van Handel; Rajkumar Sasidharan; Yuko Fujiwara; Stuart H. Orkin; Siavash K. Kurdistani; Hanna Mikkola